References
- Dimitrov DS, Marks JD. Therapeutic antibodies: current state and future trends–is a paradigm change coming soon? Methods Mol Biol 2009; 525:1-27, xiii; PMID:19252861; http://dx.doi.org/10.1007/978-1-59745-554-1_1
- The Life Sciences Report: Immuno-Oncology Promises Continued Wealth and Health: LifeTech Capital's Stephen Dunn. http://www.thelifesciencesreport.com/pub/na/immuno-oncology-promises-continued-wealth-and-health-lifetech-capitals-stephen-dunn, accessed August 20, 2015.
- Lambert N. Announcing FamPat, A New International Patent Database from Questel-Orbit. Information Today. February 14, 2005. For the search algorithms used in this study contact the author 2005.
- Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271(5256):1734-6. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8596936; PMID:8596936; http://dx.doi.org/10.1126/science.271.5256.1734
- Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005; 23(9):1117-25; PMID:16151405; http://dx.doi.org/10.1038/nbt1135
- Hanson DA, Canniff PC, Primiano MJ. Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206. Proc Am Assoc Cancer Res 2004; 45:877. Abstract 3802.
- published on the website of the US. Securities and Exchange Commission (http://www.sec.gov/Archives/edgar/data/874255/000119312504188088/dex993.htm), accessed August 20, 2015.
- published on the website of the US. Securities and Exchange Commission (http://www.sec.gov/Archives/edgar/data/874255/000119312504188088/dex992.htm), accessed August 20, 2015.
- Oncology Intelligence Report, May 19, 2010. http://oncology.healthace.com/051910/Oncology_Report_051910.pdf, accessed August 20, 2015.
- Registry number provided by ClinicalTrials.gov. In PubMed, registry numbers are included in the Secondary Source ID (SI) field, and searchable using the [si] tag.
- Ribas A. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). The Oncologist 2008; 13 Suppl 4(Supplement 4):10-5; PMID:19001146; http://dx.doi.org/10.1634/theoncologist.13-S4-10
- Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, Damle NK. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 1992; 176(6):1595-604. Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2119471&tool=pmcentrez&rendertype=abstract; PMID:1334116; http://dx.doi.org/10.1084/jem.176.6.1595
- Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Kwon ED. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004; 101(49):17174-9; PMID:15569934; http://dx.doi.org/10.1073/pnas.0406351101
- Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 19(7):813-24; PMID:17606980; http://dx.doi.org/10.1093/intimm/dxm057
- Seung E, Dudek TE, Allen TM, Freeman GJ, Luster AD, Tager AM. PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads. PloS One 2013; 8(10):e77780; PMID:24204962; http://dx.doi.org/10.1371/journal.pone.0077780
- Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Armand P. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. N Engl J Med 2014; 372(4):311-9 141206100011003; http://doi.org/10.1056/NEJMoa1411087
- PD-1 and PD-L1 inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2015. Apr 1, 2015, DelveInsight.
- Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5(12):1365-9; PMID:10581077; http://dx.doi.org/10.1038/70932
- Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192(7):1027-34. Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2193311&tool=pmcentrez&rendertype=abstract; PMID:11015443; http://dx.doi.org/10.1084/jem.192.7.1027
- Seung E, Dudek TE, Allen TM, Freeman GJ, Luster AD, Tager AM. PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads. PloS One 2013; 8(10), e77780; PMID:24204962; http://dx.doi.org/10.1371/journal.pone.0077780
- Liu X, Gao JX, Wen J, Yin L, Li O, Zuo T, Liu Y. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med 2003; 197(12):1721-30; PMID:12810690; http://dx.doi.org/10.1084/jem.20022089
- European Patent Office (EPO): Guidelines for examination, F-IV-4.1.1.
- BMS & Ono v. Merck & Co., case 1:14-cv-01131, complaint filed (D. Del. 2014).
- Roche press release, July 13, 2015, http://www.roche.com/media/store/releases/med-cor-2015-07-13.htm.
- Roche Press release, February 2, 2015, http://www.roche.com/media/store/releases/med-cor-2015-02-02.htm.
- Stumpp MT, Binz HK, Amstutz P. DARPins: a new generation of protein therapeutics. Drug Discov Today 2008; 13(15–16):695-701; PMID:18621567; http://dx.doi.org/10.1016/j.drudis.2008.04.013
- Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009; 13(3), 245-55; PMID:19501012; http://dx.doi.org/10.1016/j.cbpa.2009.04.627
- Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res 2015; 3(10):1148-57; PMID:26014098; http://doi.org/10.1158/2326-6066.CIR-15-0059
- Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in cancer Therapy. J Clin Oncol: Official Journal of the American Society of Clinical Oncology 2015; 33(17):1974-82; http://dx.doi.org/10.1200/JCO.2014.59.4358
- Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer 2014; 111(12):2214-9; PMID:25211661; http://dx.doi.org/10.1038/bjc.2014.348
- Prescribing information of Trastuzumab, Revised Version 4/2015, item 5.6.
- Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Sharma P. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 2013; 1(4):229-34; PMID:24777852; http://dx.doi.org/10.1158/2326-6066.CIR-13-0020
- Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer 2014; 111(12):2214-9; PMID:25211661; http://dx.doi.org/10.1038/bjc.2014.348
- Website of the FDA (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm, accessed August 20, 2015).
- Prescribing information of Trastuzumab, Revised Version 4/2015, item 5.6.
- University of California v. Dakocytomation California, Inc., Nos. 06-1334, -1452, 07-1202 (Fed. Cir. 2008).
- Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013; 13:5. Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3559193&tool=pmcentrez&rendertype=abstract; PMID:23390376
- Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer 2014; 111(12):2214-9; PMID:25211661; http://dx.doi.org/10.1038/bjc.2014.348
- Grosso J, Horak CE, Inzunza D, Cardona DM, Simon JS, Gupta AK, Sankar V, Park JS, Kollia G, Taube JM. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 2013; 2013:31 ([abstract 3016]).
- Callahan MK, Horak CE, Curran MA, Hollman T, Schaer DA, Yuan J, Lesokhin AM, Kitano S, Hong Q, Ariyan CE. Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. J Clin Oncol 2013; 2013:31 ([abstract 3003]).
- Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer 2014; 111(12):2214-9; PMID:25211661; http://dx.doi.org/10.1038/bjc.2014.348
- Directive 2001/83/EC (medicinal products for human use): Article 26.
- EPO Technical Board decision T0018/09, 2009, EPO Board of appeal decisions database T0018/09.
- Association for Molecular Pathology case vs. Myriad Genetics Inc., case No. Twelve-398 (2013) and Mayo Collaborative Services vs. Prometheus Laboratories, case No 10-1150 2012.
- Harrison C. Isolated DNA patent ban creates muddy waters for biomarkers and natural products. Nat Rev Drug Discov 2013; 12(8):570-1; PMID:23903213; http://dx.doi.org/10.1038/nrd4084
- Sheridan C. Immune-checkpoint inhibitors march on, now in combinations. Nat Biotechnol 2014; 32(4):297-9; PMID:24714455; http://dx.doi.org/10.1038/nbt0414-297
- Kim T, Amaria RN, Spencer C, Reuben A, Cooper ZA, Wargo JA. Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med 2014; 11(4):237-46. Retrieved from http://www.cancerbiomed.org/index.php/cocr/article/view/821/868; PMID:25610709
- European Patent Office (EPO): Guidelines for Examination, G VII, 7.
- Kim T, Amaria RN, Spencer C, Reuben A, Cooper ZA, Wargo JA. Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med 2014; 11(4):237-46. Retrieved from http://www.cancerbiomed.org/index.php/cocr/article/view/821/868; PMID:25610709
- The Life Sciences Report: Immuno-Oncology Promises Continued Wealth and Health: LifeTech Capital's Stephen Dunn. http://www.thelifesciencesreport.com/pub/na/immuno-oncology-promises-continued-wealth-and-health-lifetech-capitals-stephen-dunn, accessed August 20, 2015.
- The Life Sciences Report: Immuno-Oncology Promises Continued Wealth and Health: LifeTech Capital's Stephen Dunn. http://www.thelifesciencesreport.com/pub/na/immuno-oncology-promises-continued-wealth-and-health-lifetech-capitals-stephen-dunn, accessed August 20, 2015.
- BMS & Ono v. Merck & Co., case 1:14-cv-01131, complaint filed (D. Del. 2014).
- BMS & Ono v. Merck & Co., case 1:15-cv-00572, complaint filed (D. Del. 2015).
- 2014 Merck&Co 10-K SEC form, published on the website of the US. Securities and Exchange Commission (http://www.sec.gov/Archives/edgar/data/310158/000031015815000005/mrk1231201410k.htm), accessed August 20, 2015.
- 2014 Merck&Co 10-K SEC form published on the website of the US. Securities and Exchange Commission (http://www.sec.gov/Archives/edgar/data/310158/000031015815000005/mrk1231201410k.htm), accessed August 20, 2015.
- See the minutes of the oral proceedings of Sept 05, 2014, page 2, under https://register.epo.org/application?number=EP03741154&lng=en&tab=doclist.
- Octane Fitness, LLC v. Icon Health & Fitness, Inc., case no 12–1184 2014.
- Johnson & Johnson Vision Care v. Ciba Vision Corp, case 712 F. Supp. 2d 1285 (M.D. Fla. 2010), z4 Technologies Inc. v. Microsoft Corp, case 34 F. Supp. 2d 437 (E.D. Tex. 2006), WBIP LLC v. Kohler Co, case CA 11-10374-NMG (D. Mass. Aug. Twelve, 2013).
- World Preview 2015, Outlook to 2020. 8th edition, June 2015. Pharma market report provided by EvaluatePharma.
- 2014 Merck&Co 10-K SEC form published on the website of the US. Securities and Exchange Commission (http://www.sec.gov/Archives/edgar/data/310158/000031015815000005/mrk1231201410k.htm) accessed August 20, 2015.
- University of Mich. & Repligen v. BMS, 301 F. Supp. 2d 633 (E.D. Mich. 2003).
- Regents Univ of Mich v Bristol-Myers Squibb, case Number 04-1015 (Fed. Cir. 2004).
- Repligen et al. v. Bristol-Myers Squibb, case No. Two:06-CV-004-TJW (E.D. Tex.).
- 2008 BMS 10-K SEC form, published on the website of the US. Securities and Exchange Commission (http://www.sec.gov/Archives/edgar/data/14272/000119312509033538/d10k.htm), accessed August 20, 2015.
- European Commission, Pharmaceutical Sector Inquiry, Preliminary Report (DG Competition Staff Working Paper), 28 November 2008, page 17 (http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/preliminary_report.pdf).
- 2013 BMS 10-K SEC form, published on the website of the US. Securities and Exchange Commission (http://www.sec.gov/Archives/edgar/data/14272/000001427215000055/bmy-20141231´10xk.htm), accessed August 20, 2015.
- 2009 Repligen 10-K SEC form, published on the website of the US. Securities and Exchange Commission (http://www.sec.gov/Archives/edgar/data/730272/000119312515095569/d854858d10k.htm), accessed August 20, 2015.